Science Explorer Back to mapMap
Discussion
Researcher · University of California, San Francisco · United States

David Diebold

David Diebold publishes mostly in Molecular Biology, Immunology and Oncology, on topics such as CAR-T cell therapy research, Extracellular vesicles in disease and RNA Interference and Gene Delivery.

ORCID 0000-0002-6857-767X OpenAlex
World rank
#2,413,801
of 7,710,434 ranked researchers
Rank in United States
#715,360
of 1,627,098
Works
21
Citations
240
Citations per work
11.4
h-index
7
i10-index 6Top 91% in Molecular Biology
David Diebold

What does David Diebold research?

David Diebold's work is mostly in Biochemistry, Genetics and Molecular Biology (38%), Immunology and Microbiology (18%), Medicine (13%).

Life Sciences: 13 works · 62.2% of their workBiochemistry, Genetics and Molecular Biology: 8 works · 37.7% of their workMolecular Biology: 7 works · 33.3% of their workCancer Research: 1 works · 4.4% of their workImmunology and Microbiology: 4 works · 17.8% of their workImmunology: 4 works · 17.8% of their workNeuroscience: 1 works · 6.7% of their workNeurology: 1 works · 6.7% of their workEverything else: 4 works · 17.8% of their workHealth Sciences: 3 works · 13.3% of their workMedicine: 3 works · 13.3% of their workOncology: 3 works · 13.3% of their workPhysical Sciences: 1 works · 6.7% of their workEngineering: 1 works · 6.7% of their workBiomedical Engineering: 1 works · 6.7% of their workTHEIR WORKDavid Diebold21works
Life Sciences62%Physical Sciences7%Health Sciences13%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology837.7%
    2. Immunology and Microbiology417.8%
    3. Neuroscience16.7%
  2. Everything else417.8%
    1. Medicine313.3%
    1. Engineering16.7%
  1. 1Molecular Biology33% of their works
  2. 2Immunology18% of their works
  3. 3Oncology13% of their works
  4. 4Biomedical Engineering7% of their works
  5. 5Neurology7% of their works
  6. 6Cancer Research4% of their works

Research topics

Which keywords describe David Diebold's research?

The keywords of their largest research topics: Cancer, Cancer Immunotherapy, Immunotherapy, CAR T Cells, Chimeric Antigen Receptor, Exosomes, Extracellular Vesicles and Immunity.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most.

All 21 words, with their numbers
  1. Cancer82 topics
  2. Cancer Immunotherapy82 topics
  3. Immunotherapy82 topics
  4. CAR T Cells61 topic
  5. Chimeric Antigen Receptor61 topic
  6. Exosomes51 topic
  7. Extracellular Vesicles51 topic
  8. Immunity52 topics
  9. Innate Immunity52 topics
  10. Activation31 topic
  11. Macrophage31 topic
  12. Microglia31 topic
  13. Neuroinflammation31 topic
  14. RNA Interference31 topic
  15. siRNA Delivery31 topic
  16. Alternative Splicing21 topic
  17. Antigen Presentation21 topic
  18. Dendritic Cells21 topic
  19. Glioblastoma21 topic
  20. RNA-Binding Proteins21 topic
  21. Temozolomide21 topic

Where does David Diebold work?

David Diebold's main affiliation in the publication record is University of California, San Francisco, United States.

How many publications and citations does David Diebold have?

OpenAlex counts 21 works and 240 citations for David Diebold, an h-index of 7, ranking #2,413,801 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about David Diebold. Posts are plain text and can be reported.